GlassScriptPhysician profile
Kenneth Aaron Mair
NPI 1588696678
$50,429.89
in general payments reported to CMS, 2019-2025
72 companies · $2,913 in 2025
The $2,913 reported for 2025 was more than what 83% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30K · 2020: $5,611 · 2021: $2,536 · 2022: $2,908 · 2023: $3,481 · 2024: $3,046 · 2025: $2,913.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,398 · Education: $42.39.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,398.35 |
| Education | $42.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $23,137.27 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $10,723.62 | 2019-2025 | Mounjaro, Lyumjev, Jardiance |
| Abbott Laboratories | $1,774.38 | 2019-2025 | Freestyle Libre, Octrode |
| Astrazeneca Pharmaceuticals LP | $1,587.61 | 2019-2023 | Farxiga |
| Amgen INC. | $1,518.44 | 2019-2025 | Tepezza, Evenity, Repatha |
| Novo Nordisk INC | $1,162.96 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $942.26 | 2019-2025 | |
| Mannkind Corporation | $827.09 | 2019-2025 | Afrezza |
| Abbvie INC. | $797.41 | 2019-2025 | |
| Insulet Corporation | $474.41 | 2019-2025 | Omnipod |
| Amarin Pharma, INC. | $453.64 | 2019-2022 | |
| Dexcom, INC. | $442.82 | 2019-2025 | Dexcom G6 Transmitter |
| Recordati_rare_diseases_inc. | $386.19 | 2020-2025 | Isturisa, Signifor Lar |
| Tandem Diabetes Care, INC. | $331.51 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Esperion Therapeutics, INC. | $313.08 | 2020-2025 | Nexletol |
Show all 72 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $275.95 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $272.38 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Radius Health, INC. | $246.44 | 2019-2025 | Tymlos |
| Novartis Pharmaceuticals Corporation | $246.08 | 2023-2025 | |
| Antares Pharma, INC. | $229.86 | 2019-2024 | Xyosted, Tlando, Nocdurna |
| Horizon Therapeutics Plc | $220.07 | 2021-2023 | Tepezza |
| Corcept Therapeutics | $210.90 | 2019-2025 | Korlym |
| Endo Pharmaceuticals INC. | $202.82 | 2020-2022 | |
| Medtronic Minimed, INC. | $189.30 | 2019-2020 | |
| Ibsa Pharma INC. | $185.53 | 2019-2024 | Tirosint, Licart, Tirosint |
| Alexion Pharmaceuticals, INC. | $175.31 | 2020-2025 | Strensiq |
| Ascendis Pharma Endocrinology INC | $173.46 | 2023-2025 | Yorvipath |
| Becton, Dickinson and Company | $169.43 | 2019-2022 | |
| Sequel Med Tech, LLC | $147.41 | 2025 | Twiist |
| Medtronic, INC. | $140.59 | 2021-2025 | Minimed 780g |
| Zealand Pharma US, INC. | $140.34 | 2021-2022 | |
| Chiesi USA, INC. | $138.54 | 2024-2025 | Mycapssa, Myalept |
| Amneal Pharmaceuticals LLC | $134.10 | 2019-2024 | Unithroid |
| Cequr Corporation | $129.77 | 2022-2025 | Cequr Simplicity |
| Beta Bionics, INC. | $125.09 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Lifescan, INC. | $120.49 | 2020-2023 | |
| Neurocrine Biosciences, INC. | $113.59 | 2024-2025 | |
| Tolmar, INC. | $112.61 | 2023-2024 | |
| Averitas Pharma INC. | $99.80 | 2023 | Qutenza |
| Verity Pharmaceuticals INC. | $98.65 | 2024-2025 | Tlando, Trelstar |
| Ultragenyx Pharmaceutical INC. | $97.88 | 2020-2023 | |
| Madrigal Pharmaceuticals | $93.91 | 2025 | Rezdiffra |
| Embecta Corp. | $87.15 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Halozyme INC | $79.75 | 2023 | |
| Companion Medical, INC. | $74.52 | 2019-2020 | |
| Shire North American Group INC | $68.36 | 2019 | |
| Pfizer INC. | $63.40 | 2019-2023 | |
| Clarus Therapeutics INC. | $50.17 | 2021 | |
| Amryt Pharma Holdings LTD | $50.16 | 2023 | Mycapssa |
| Janssen Pharmaceuticals, INC | $48.44 | 2019 | |
| Ascensia Diabetes Care US INC. | $47.42 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $47.25 | 2020-2021 | |
| Valeritas, INC. | $44.38 | 2019 | |
| Amphastar Pharmaceuticals, INC. | $39.60 | 2024 | |
| Nevro Corp. | $37.32 | 2023 | Senza |
| Intuity Medical INC | $35.01 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.33 | 2020-2022 | |
| Roche Diabetes Care, INC. | $27.86 | 2019-2020 | |
| Endo USA, INC. | $22.83 | 2025 | Aveed |
| Ipsen Biopharmaceuticals, INC | $21.98 | 2019 | |
| Globus Medical, INC. | $21.93 | 2025 | Senza |
| Rhythm Pharmaceuticals, INC. | $19.05 | 2025 | Imcivree |
| Enterra Medical, INC. | $18.04 | 2024 | |
| Astellas Pharma US INC | $17.19 | 2025 | Veozah |
| Eisai INC. | $17.18 | 2020 | |
| Boston Scientific Corporation | $15.97 | 2020 | |
| Glaxosmithkline, LLC. | $15.61 | 2025 | Shingrix, Arexvy |
| Avvisto Therapeutics, LLC | $14.76 | 2025 | Cycloset |
| Althera Pharmaceuticals LLC | $13.75 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.92 | 2020 | |
| Currax Pharmaceuticals LLC | $12.75 | 2022 | |
| Grt US Holding, INC. | $11.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Mair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.